DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M.
Yao J, et al. Among authors: crabtree js.
Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161.
Oncologist. 2022.
PMID: 35983951
Free PMC article.
Review.